May 31, 2017
Merck will present data for KEYTRUDA® Across 16 Types of Cancer at the 2017 ASCO Annual Meeting Researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including NSCLC, melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric […]
May 31, 2017
Pfizer will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 moA, at the ASCO in Chicago from June 2-6, 2017. New data will be featured in 9 oral presentations from company-sponsored clinical trials, including a late-breaker on the investigational compound […]
May 31, 2017
Janssen will present new data for both approved and investigational oncology compounds at ASCO 2017 Annual Meeting. 19 company-sponsored abstracts have been accepted for presentation, including for abiraterone acetate, daratumumab and ibrutinib. Most notably, Phase 3 pivotal trial results for abiraterone acetate will be featured in the ASCO Press Briefing […]
May 31, 2017
Celgene will demonstrate its broad range of Oncology Clinical Development Program evaluating its investigational pipeline & marketed products at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative […]
May 30, 2017
Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies […]
May 30, 2017
AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology […]